Abstract

Short Communication

The “Calcium Paradox” Due To Ca2+/Camp Interaction: New Insights for the Neuroscience Field

Leandro Bueno Bergantin* and Afonso Caricati-Neto

Published: 21 February, 2017 | Volume 1 - Issue 1 | Pages: 012-015

In the cardiovascular field, tachycardia and increment of catecholamine plasma levels (sympathetic hyperactivity) have been reported by hypertensive patients that use L-type Ca2+ channel blockers (CCBs) since 70´s. Our discovery of the involvement of interaction between the intracellular signalling pathways mediated by Ca2+ and cAMP (Ca2+/cAMP interaction) revealed that this phenomenon (sympathetic hyperactivity) was resulting of increase of transmitter release from sympathetic neurons stimulated by CCBs due to its interference on the Ca2+/cAMP interaction. In the neuroscience field, this discovery has produced new paths for the understanding of the cellular and molecular mechanisms involved in the pathogenesis of neurodegenerative diseases, such as Alzheimer´s and Parkinson’s diseases. In this way, novel journeys for the development of new pharmacological strategies more effective for the treatment of neurodegenerative diseases may be initiated.

Read Full Article HTML DOI: 10.29328/journal.jnnd.1001002 Cite this Article Read Full Article PDF

Keywords:

Ca2+/cAMP interaction; “Calcium paradox”; Neurodegenerative diseases

References

 

  1. Reuse of portions or extracts from the article in other works- https://www.elsevier.com/__data/assets/pdf_file/0007/55654/AuthorUserRights.pdf

 

  1. REFERENCES
  2. Chern YJ, Kim KT, Slakey LL, Westhead EW. Adenosine receptors activate adenylate cyclase and enhance secretion from bovine adrenal chromaffin cells in the presence of forskolin. J Neurochem. 1988; 50: 1484-1493. Ref.: https://goo.gl/D3U5F0
  3. Douglas WW, Rubin RP. The role of calcium in the secretory response of the adrenal medulla to acetylcholine. J Physiol. 1961; 159: 40-57. Ref.: https://goo.gl/Lwekpm
  4. Baker PF, Knight DE. Calcium-dependent exocytosis in bovine adrenal medullary cells with leaky plasma membranes. Nature. 1978; 276: 620-622. Ref.: https://goo.gl/bvf8DR
  5. Neher E, Zucker RS. Multiple calcium-dependent processes related to secretion in bovine chromaffin cells. Neuron. 1993; 10: 21-30. Ref.: https://goo.gl/3fvzjy
  6. Caricati-Neto A, García AG, Bergantin LB. Pharmacological implications of the Ca2+/cAMP signalling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. Pharmacol Res Perspect. 2015; 3: e00181. Ref.: https://goo.gl/UiQrGs
  7. Bergantin LB, Souza CF, Ferreira RM, Smaili SS, Jurkiewicz NH, et al. Novel model for “calcium paradox” in sympathetic transmission of smooth muscles: role of cyclic AMP pathway. Cell Calcium. 2013; 54: 202-212. Ref.: https://goo.gl/HHou6F        
  8. Bergantin LB, Jurkiewicz A, García AG, Caricati-Neto A. A Calcium Paradox in the Context of Neurotransmission. Journal of Pharmacy and Pharmacology. 2015; 3: 253-261. Ref.: https://goo.gl/ltkVhv
  9. Bergantin LB, Caricati-Neto A. Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca2+/cAMP intracellular signalling interaction. Eur J Pharmacol. 2016; 788: 255-260. Ref.: https://goo.gl/u21xBi
  10. Grossman E, Messerli FH. Effect of calcium antagonists on sympathetic activity. Eur Heart J. 1998; 19: F27-F31. Ref.: https://goo.gl/BQkkG1
  11. Kreye VA, Luth JB. Proceedings: verapamil-induced phasic contractions of the isolated rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 1975; 287: R43. Ref.: https://goo.gl/Z07NA4
  12. French AM, Scott NC. A comparison of the effects of nifedipine and verapamil on rat vas deferens. Br J Pharmacol. 1981; 73: 321-323. Ref.: https://goo.gl/d8wrcd
  13. Moritoki H, Iwamoto T, Kanaya J, Maeshiba Y, Ishida Y, et al.  Verapamil enhances the non-adrenergic twitch response of rat vas deferens. Eur J Pharmacol. 1987; 140: 75-83. Ref.: https://goo.gl/OKoviM
  14. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med. 1995; 1: 244-248. Ref.: https://goo.gl/MiganR
  15. Xiao L, O'Callaghan JP, O'Donnell JM. Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test. J Pharmacol Exp Ther. 2011; 338: 641-647. Ref.: https://goo.gl/14xO4A
  16. Bergantin LB, Caricati-Neto A. Novel Insights for Therapy of Parkinson’s disease: Pharmacological Modulation of the Ca2+/cAMP Signalling Interaction. Austin Neurol & Neurosci. 2016; 1: 1009. Ref.: https://goo.gl/ujivdj
  17. Bergantin LB, Caricati-Neto A. Recent advances in pharmacotherapy of neurological and psychiatric disorders promoted by discovery of the role of Ca2+/cAMP signaling interaction in the neurotransmission and neuroprotection. Adv Pharmac J. 2016; 1: 66.
  18. Halls ML, Cooper DM. Adenylyl cyclase signalling complexes - Pharmacological challenges and opportunities. Pharmacol Ther. 2017; 7258: 30011-30016. Ref.: https://goo.gl/VDeVKV
  19. Cooper DM, Mons N, Karpen JW. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature. 1995; 374: 421-424. Ref.: https://goo.gl/OVc1JP
  20. Bereczki E, Francis PT, Howlett D, Pereira JB, Höglund K, et al. Synaptic proteins predict cognitive decline in Alzheimer`s disease and Lewy body dementia. Alzheimers Dement. 2016; 12: 1149-1158. Ref.: https://goo.gl/pch8Cq
  21. Clare R, King VG, Wirenfeldt M, Vinters HV. Synapse loss in dementias. J Neurosci Res. 2010; 88: 2083-2090. Ref.: https://goo.gl/5sJRu7

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?